Form 10-Q Evoke Pharma Inc For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Form 10-Q Evoke Pharma Inc For: Jun 30
August 16, 2016 8:43 AM EDT
Noble Financial affirms Evoke Pharma (Nasdaq: EVOK) with a Hold rating following Q2 results issued Monday night.
Analyst Nathan Cali noted the following on Tuesday:
Operational costs incrementally lower. August 15th, 2016, reported second quarter financial results; no revenues as expected; SG&A $802,655...
More
August 15, 2016 4:35 PM EDT
Evoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43).
As of June 30, 2016, the Company's cash and cash equivalents were approximately $4.1 million.
Dave Gonyer, R.Ph., President and CEO, stated, Following the results of our recently concluded Phase 3 study of Gimoti, our nasally delivered metoclopramide product for the treatment of diabetic gastroparesis in women, we continue to analyze the incoming data to further understand the... More
